Premium
P3‐277: IVIg treatment in Alzheimer's and Lewy body disease: Potential disease delaying effect
Author(s) -
Hara Junko,
Masatsugu Kaitlin,
Shankle William R.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1777
Subject(s) - medicine , memantine , dementia , disease , lewy body , clinical endpoint , apolipoprotein e , retrospective cohort study , stage (stratigraphy) , oncology , gastroenterology , clinical trial , paleontology , biology
the brain is believed to be pivotal to treat the AD patients. Based on Ab hypothesis, Ab(1-42) monomers released from APP by band g-secretases are gradually aggregated to oligomers, protofibrils, and fibrils. Ab(1-42) aggregates such as oligomers and fibrils deposit in the brain causing strong neuronal toxicity. In addition, it was recently reported that oligomers might be more toxic than fibrils, and the oligomers are becoming the target for the development of AD treatments. Methods: Here we report pharmacology, ADME and toxicity tests of a novel aminostyrylbenzofuran derivative with potent inhibitory activities for amyloidogenesis. Results: KMS88009 showed outstanding results in in vitro Inhibition activities of formation of Ab42 plague, fear conditioning, water maze, Y-maze, noble object recognition, hERG assay, ADME and toxicity. Conclusions: In particular, KMS88009 is a promising AD drug candidate as an amyloidogenesis modulator.